Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENOB
- Price
- -
- Stock movement down
- -0.06 (-3.88%)
- Company name
- Enochian Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 82.44M
- Ent value
- 85.29M
- Price/Sales
- -
- Price/Book
- 1.14
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 61.45%
- 1 year return
- -45.19%
- 3 year return
- -31.23%
- 5 year return
- -18.03%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
ENOB does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.14 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.71M |
| EPS (TTM) | -3.70 |
| FCF per share (TTM) | -0.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -114.39M |
| Net income (TTM) | -194.38M |
| EPS (TTM) | -3.70 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.17M |
| Net receivables | 0.00 |
| Total current assets | 9.57M |
| Goodwill | 11.64M |
| Intangible assets | 44.27K |
| Property, plant and equipment | 0.00 |
| Total assets | 84.63M |
| Accounts payable | 1.40M |
| Short/Current long term debt | 7.02M |
| Total current liabilities | 6.45M |
| Total liabilities | 12.01M |
| Shareholder's equity | 72.62M |
| Net tangible assets | 70.32M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -6.43M |
| Capital expenditures (TTM) | 28.79K |
| Free cash flow (TTM) | -6.46M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -267.67% |
| Return on Assets | -229.67% |
| Return on Invested Capital | -246.91% |
| Cash Return on Invested Capital | -8.20% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ENOB | S&P500 | |
| Current price drop from All-time high | -88.21% | -6.66% |
| Highest price drop | -96.81% | -56.47% |
| Date of highest drop | 29 Jun 2023 | 9 Mar 2009 |
| Avg drop from high | -51.11% | -11.07% |
| Avg time to new high | 47 days | 12 days |
| Max time to new high | 706 days | 1805 days |
COMPANY DETAILS
Marketcap
82.44M
Marketcap category
Small-cap
Description
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Employees
22
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Los Angeles
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner